STAAR Surgical (STAA) Stock Price, News & Analysis

Company Overview

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Key Stats

• Today's Range: $25.97 to $26.75
• 50-Day Range: $17.76 to $28.57
• 52-Week Range: $13.50 to $33.28
• Volume: 292,678 shs
• Average Volume: 1.17 million shs
• Market Capitalization: $1.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.67
• Consensus Rating: Reduce

STAAR Surgical Stock Analysis - MarketRank™

STAAR Surgical scored higher than 61% of companies evaluated by MarketBeat, and ranked 449th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

STAAR Surgical has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on no buy ratings, 10 hold ratings, and 1 sell rating.

Downside Risk

STAAR Surgical has a consensus price target of $20.67, representing about 22.6% downside from its current price of $26.70.

Amount of Analyst Coverage

STAAR Surgical has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for STAAR Surgical are expected to grow in the coming year, from ($1.14) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of STAAR Surgical is -13.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of STAAR Surgical is -13.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

STAAR Surgical has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.88% of the outstanding shares of STAAR Surgical have been sold short.

Short Interest Ratio / Days to Cover

STAAR Surgical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in STAAR Surgical has recently decreased by 2.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

STAAR Surgical does not currently pay a dividend.

Dividend Growth

STAAR Surgical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.73

Percentage of Shares Shorted

7.88% of the outstanding shares of STAAR Surgical have been sold short.

Short Interest Ratio / Days to Cover

STAAR Surgical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in STAAR Surgical has recently decreased by 2.51%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.19

News Sentiment

STAAR Surgical has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for STAAR Surgical this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for STAA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added STAAR Surgical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, STAAR Surgical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.59% of the stock of STAAR Surgical is held by insiders.

Percentage Held by Institutions

96.70% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STAA Stock Analysis - Frequently Asked Questions

How have STAA shares performed this year?

STAAR Surgical's stock was trading at $24.29 at the start of the year. Since then, STAA shares have increased by 9.9% and is now trading at $26.6950.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical Company (NASDAQ:STAA) announced its quarterly earnings results on Wednesday, August, 7th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by $0.09. The business's revenue was up 7.3% on a year-over-year basis.
Read the conference call transcript.

Is STAAR Surgical buying back stock?

STAAR Surgical's Board of Directors initiated a share buyback plan on Friday, May 16th 2025, which allows the company to buy back $30,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 3.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued.

Does STAAR Surgical have any subsidiaries?

The following companies are subsidiaries of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.

Who are STAAR Surgical's major shareholders?

STAAR Surgical's top institutional shareholders include Assenagon Asset Management S.A. (0.03%) and GAMMA Investing LLC. Insiders that own company stock include Broadwood Partners, LP, Keith Holliday, Aimee S Weisner, Arthur C Butcher and Elizabeth Yeu Lin.
View institutional ownership trends.

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that STAAR Surgical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Palo Alto Networks (PANW) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 10/09/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:STAA
• CIK: 718937
• Web: www.staar.com
• Phone: (626) 303-7902
• Fax: 626-303-2962
• Employees: 1,211
• Year Founded: 1982

Price Target and Rating

• Average Price Target for STAAR Surgical: $20.67
• High Price Target: $28.00
• Low Price Target: $16.00
• Potential Upside/Downside: -22.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.21 million
• Net Margins: -42.45%
• Pretax Margin: -43.47%
• Return on Equity: -16.11%
• Return on Assets: -12.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.94
• Quick Ratio: 4.05

Sales & Book Value

• Annual Sales: $313.90 million
• Price / Sales: 4.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.06 per share
• Price / Book: 3.29

Miscellaneous

• Outstanding Shares: 49,350,000
• Free Float: 49,063,000
• Market Cap: $1.31 billion
• Optionable: Optionable
• Beta: 0.82